PT83655B - Dna sequences recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides - Google Patents

Dna sequences recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides

Info

Publication number
PT83655B
PT83655B PT83655A PT8365586A PT83655B PT 83655 B PT83655 B PT 83655B PT 83655 A PT83655 A PT 83655A PT 8365586 A PT8365586 A PT 8365586A PT 83655 B PT83655 B PT 83655B
Authority
PT
Portugal
Prior art keywords
polypeptides
processes
inhibiting substance
dna sequences
recombinant dna
Prior art date
Application number
PT83655A
Other languages
English (en)
Other versions
PT83655A (en
Inventor
Richard L Cate
Patricia K Donahoe
Original Assignee
Biogen Nv
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Nv, Gen Hospital Corp filed Critical Biogen Nv
Publication of PT83655A publication Critical patent/PT83655A/pt
Publication of PT83655B publication Critical patent/PT83655B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PT83655A 1985-10-30 1986-10-30 Dna sequences recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides PT83655B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/792,880 US5047336A (en) 1985-10-30 1985-10-30 DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

Publications (2)

Publication Number Publication Date
PT83655A PT83655A (en) 1986-11-01
PT83655B true PT83655B (en) 1988-11-29

Family

ID=25158349

Family Applications (1)

Application Number Title Priority Date Filing Date
PT83655A PT83655B (en) 1985-10-30 1986-10-30 Dna sequences recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides

Country Status (13)

Country Link
US (1) US5047336A (pt)
EP (1) EP0221761B1 (pt)
JP (2) JPH0720431B2 (pt)
KR (1) KR870004143A (pt)
AT (1) ATE119915T1 (pt)
AU (1) AU606584B2 (pt)
CA (1) CA1307753C (pt)
DE (1) DE3650266T2 (pt)
DK (1) DK517986A (pt)
HU (1) HUT43627A (pt)
IL (1) IL80451A0 (pt)
PT (1) PT83655B (pt)
ZA (1) ZA868251B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
AU622891B2 (en) * 1985-10-30 1992-04-30 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5349058A (en) * 1990-02-06 1994-09-20 E. R. Squibb & Sons, Inc. Nucleic acid encoding human mevalonate kinase
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
US5310880A (en) * 1991-04-12 1994-05-10 The General Hospital Corporation Purification of Mullerian inhibiting substance
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
EP1109570B1 (en) * 1998-08-31 2005-10-19 Biogen, Inc. Modulation of memory effector t-cells with a cd2 binding agent
US20020119921A1 (en) * 1999-03-31 2002-08-29 Michael Streit Thrombospondin-2 and uses thereof
WO2001019387A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
AU2001231196A1 (en) * 2000-01-27 2001-08-07 The General Hospital Corporation Delivery of therapeutic biological from implantable tissue matrices
CA2451765A1 (en) * 2001-06-05 2002-12-12 Karen K. Oishi Gene expression and production of tgf-b proteins including bioactive mullerian inhibiting substance from plants
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US20040151693A1 (en) * 2002-08-23 2004-08-05 The General Hospital Corporation Use of mullerian inhibiting substance and interferon for treating tumors
US20070172478A1 (en) * 2004-02-06 2007-07-26 Astellas Us Llc Methods of treating skin disorders
BRPI0510691A (pt) * 2004-05-04 2007-12-26 Genaissance Pharmaceuticals marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20060162026A1 (en) * 2004-12-23 2006-07-20 Karen Oishi Expressing TGF-beta proteins in plant plastids
US20060216294A1 (en) * 2005-03-24 2006-09-28 Mclennan Ian S Method of modulation
EP1940450A4 (en) * 2005-10-26 2010-12-29 Otago Innovation Ltd MODULATION METHOD
WO2008116161A2 (en) 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
EP2676678A1 (en) 2007-07-17 2013-12-25 The General Hospital Corporation Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof
ITRM20120285A1 (it) 2012-06-18 2013-12-19 Alfonso Baldi Ormone anti-mulleriano.
EP2968470B1 (en) * 2013-03-12 2020-10-28 The General Hospital Corporation Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
RU2616273C1 (ru) * 2016-04-21 2017-04-13 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Синтетическая ДНК, кодирующая антимюллеров гормон человека, содержащий ее экспрессионный вектор pTVK4pu/MISOPT и штамм клеток яичников китайского хомячка CHO-MIS - продуцент рекомбинантного антимюллерового гормона человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510131A (en) * 1981-07-29 1985-04-09 The General Hospital Corporation Purified Mullerian Inhibiting Substance and method of use
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4487833A (en) * 1982-03-01 1984-12-11 The General Hospital Corporation Method of preparing hybridomas and of purifying immunogenic materials
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

Also Published As

Publication number Publication date
DE3650266T2 (de) 1995-08-31
EP0221761B1 (en) 1995-03-15
DK517986A (da) 1987-05-01
JP2541761B2 (ja) 1996-10-09
DE3650266D1 (de) 1995-04-20
IL80451A0 (en) 1987-01-30
ZA868251B (en) 1988-09-28
HUT43627A (en) 1987-11-30
EP0221761A2 (en) 1987-05-13
JPH0720431B2 (ja) 1995-03-08
KR870004143A (ko) 1987-05-07
EP0221761A3 (en) 1988-10-12
AU606584B2 (en) 1991-02-14
US5047336A (en) 1991-09-10
JPS62190084A (ja) 1987-08-20
ATE119915T1 (de) 1995-04-15
CA1307753C (en) 1992-09-22
PT83655A (en) 1986-11-01
JPH06133793A (ja) 1994-05-17
DK517986D0 (da) 1986-10-29
AU6452186A (en) 1987-05-07

Similar Documents

Publication Publication Date Title
PT83655B (en) Dna sequences recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
ZA831094B (en) Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
ES8703490A1 (es) Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano
HK1013847A1 (en) Gdf-1 and uog-1 proteins
ES8400770A1 (es) Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano.
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
ZA86217B (en) Dna sequences,recombinant dna molecules and processes for producing human lipocortin-like polypeptides
PL254399A1 (en) Method of isolating a neoplasm necrosis effecting factor
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
IL193886A (en) Antibodies that bind to ldcam sequences
IL140938A0 (en) Molecules designated b7l-1
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
ES8708013A1 (es) Procedimiento para preparar plasmidos de expresion prhw11 y prhw12
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
ES8800353A1 (es) Procedimiento de clonacion de factor humano viii-r.
EP0960128A4 (en) Gene product overexpressed in cancer cells
ZA84512B (en) Dna sequences,recombinant dna molecules and processes for producing human interleukin two-like polypeptides
GEP19970665B (en) Processes for producing human interferon-like polypeptides
IL65623A0 (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing poly-peptides coded thereby
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
ZA812189B (en) Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
NO871737D0 (no) Rekombinant virus, polypeptid samt dna molekyl med kodingssekvens for dette polypeptid.